clinical-lymphoma-myeloma-leukemia.com
Evaluating the real-world value of daratumumab addition to multiple myeloma induction therapy by real-world minimal residual disease assessment and extended genetic profiling
Daratumumab, bortezomib, thalidomide, and dexamethasone (Dara-VTd) is the current
standard of care in Europe based on the CASSIOPEIA study, which demonstrated improved
depth of response and progressio...